Anokion Company
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
Investors
.png)
Connections
Headquarters:
Ecublens, Vaud, Switzerland, Europe
Founded Date:
2010-01-01
Industry:
Cell, Gene & Biologics Therapeutics
Employee Number:
11-50
Super Industry:
Biopharma & Life Science Tools
Investors:
Celgene, Foundation for Innovation and Technology (FIT), Novartis Venture Fund, Novo Ventures, Versant Ventures
Ipo Status:
private
City:
Ecublens
Region:
Vaud
Country:
Switzerland
Founders:
Jeffrey A. Hubbell, Kristen M. Lorentz, Melody Swartz, Oscar Buset, Stephan Kontos